NKTR NEKTAR THERAPEUTICS
Price Chart
Executive Summary
Two top executives at Nektar Therapeutics (CEO Howard Robin and Chief R&D Officer Jonathan Zalevsky) sold a combined $42K of stock on May 19, 2026, at $65.51 per share. This insider selling occurred just 13 days after the company filed a $150M at-the-market equity offering (424B5), representing ~6.5% dilution of the $2.3B market cap. The cluster is small in absolute dollar terms but gains significance from the proximity to a large capital raise, which insiders were likely aware of before the public filing.
Key Financial Metrics
Actionable Insight
The proximity of insider selling to a $150M ATM offering is a bearish signal. Insiders sold at $65.51, 23% below the offering reference price, suggesting they see further downside or want to lock in gains before dilution hits. Monitor for additional insider sales and the pace of ATM draws. The stock has already declined significantly since the offering announcement, and this cluster reinforces negative sentiment.
Key Facts
- CEO Howard Robin sold 444 shares for $29K on May 19, 2026
- Chief R&D Officer Jonathan Zalevsky sold 199 shares for $13K on May 19, 2026
- Total insider sales: $42K, representing ~0.002% of $2.3B market cap
- Sales occurred 13 days after Nektar filed a $150M at-the-market equity offering (424B5 on May 8, 2026)
- The ATM offering could dilute existing shareholders by ~6.5% at current prices
- Both insiders sold at $65.51, well below the $85.09 reference price in the May 8 prospectus supplement
- Interim CFO Sandra Gardiner retired effective May 15, 2026, replaced by Linda Rubinstein
Financial Impact
Insider sales of $42K are trivial relative to $2.3B market cap, but the $150M ATM offering represents ~6.5% potential dilution. The stock has fallen ~23% from the $85.09 reference price to $65.51 since the offering was filed.
Risk Factors
- Further dilution from the $150M ATM offering could pressure the stock
- Insider selling by both CEO and Chief R&D Officer may signal lack of confidence in near-term prospects
- Stock has fallen 23% since the ATM filing, indicating market concern about dilution and fundamentals
- CFO transition adds execution risk during a capital raise period
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NKTR-1779402446634 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
19d ago
|
Insider Cluster
| $66.61 $63.86 | ▲ +4.13% | ▲ +5.79% | $56.62 (+15.00%) |
|
May 8, 2026
4w ago
|
8-K
| $78.72 $68.43 | ▲ +13.07% | ▲ +12.99% | $56.62 (+28.07%) |
|
May 7, 2026
4w ago
|
8-K
| $81.89 $74.33 | ▼ −9.23% | ▼ −10.70% | $56.62 (−30.86%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $86.74 $86.89 | ▲ +0.17% | ▼ −0.23% | $56.62 (−34.72%) |
|
Apr 23, 2026
6w ago
|
8-K
| $91.26 $83.20 | ▼ −8.83% | ▼ −10.31% | $56.62 (−37.96%) |
|
Apr 23, 2026
6w ago
|
424B5
| $91.26 $83.20 | ▼ −8.83% | ▼ −10.31% | $56.62 (−37.96%) |
|
Apr 20, 2026
7w ago
|
424B5
| $98.16 $83.81 | ▼ −14.62% | ▼ −15.70% | $56.62 (−42.32%) |
|
Apr 20, 2026
7w ago
|
8-K
| $98.16 $83.81 | ▼ −14.62% | ▼ −15.70% | $56.62 (−42.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access